Adjunctive CB1 Agonist Nabilone in Inpatients With Active Suicidal Ideation

Withdrawn before enrolling · Phase 2 · Has a placebo group

Conditions studied: Suicidal Ideation

In brief

Suicide is a major crisis worldwide with rates projected to continue to increase. There is currently a dearth of novel pharmacologic treatment options for suicide available on the market. The endocannabinoid system has been recently shown to be associated with mood disorders including suicidality. The aim of the study is to determine whether treatment with Nabilone is capable of reducing suicidal ideation in adults after 3 days.

Key facts

Study ID

NCT04807829

Run by

The University of Texas Health Science Center, Houston

People needed

0

Starts

2021-04-01

Expected to finish

2022-04-01

Last updated by the study team

2021-09-22

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Able to provide written informed consent
• Current suicidal ideation
• Columbia Suicide Severity Rating Scale (CSSRS) score of ≥ 4 and Scale for Suicide Ideation (SSI) first 5 items, score of ≥4
• Current major depressive episode as evidenced by MADRS score ≥ 20

You may not qualify if…

• Current diagnosis of a Diagnostic and Statistical Manual V (DSM-V) psychotic disorder, psychotic symptoms, or personality disorder.
• Recent (<72 hrs) use of illicit substances
• Comorbid substance use disorder diagnosis
• Urine drug screen (UDS) positive for tetrahydrocannabinol (THC)
• Pregnant or nursing women
• Unstable medical condition

Where it is running

• Harris County Psychiatric Center (HCPC) — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.